Aethlon Medical (AEMD) to Announce Earnings on Wednesday

Aethlon Medical (NASDAQ:AEMD) will likely be announcing its Q1 2027 results before the market opens on Wednesday, August 12th. Analysts expect Aethlon Medical to announce earnings of ($0.7850) per share for the quarter. Parties can find conference call details on the company’s upcoming Q1 2027 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

Aethlon Medical Trading Up 5.6%

Shares of Aethlon Medical stock opened at $3.52 on Wednesday. The stock has a 50 day moving average of $6.24 and a 200 day moving average of $9.38. Aethlon Medical has a 12 month low of $2.62 and a 12 month high of $137.00. The firm has a market cap of $11.44 million, a PE ratio of -0.24 and a beta of 1.41.

Hedge Funds Weigh In On Aethlon Medical

An institutional investor recently bought a new position in Aethlon Medical stock. Citadel Advisors LLC bought a new position in Aethlon Medical, Inc. (NASDAQ:AEMD) in the third quarter, according to the company in its most recent filing with the SEC. The fund bought 95,084 shares of the medical equipment provider’s stock, valued at approximately $71,000. Citadel Advisors LLC owned 36.57% of Aethlon Medical as of its most recent filing with the SEC. 1.99% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aethlon Medical in a report on Friday, July 17th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Reduce”.

Aethlon Medical Company Profile

Aethlon Medical, Inc (NASDAQ: AEMD) is a clinical‐stage biotechnology company focused on developing novel immunotherapeutic medical devices to address life‐threatening diseases. The company’s lead product candidate, the Hemopurifier®, is an extracorporeal affinity device designed to remove circulating viruses and immunosuppressive exosomes from the bloodstream. By targeting glycosylated pathogens and exosomes, Aethlon aims to restore immune function and improve patient outcomes in oncology and infectious disease settings.

The Hemopurifier platform leverages proprietary lectin affinity technology to selectively bind and eliminate harmful particles without depleting healthy blood components.